NL300221I2 - Dihydrospirorenon als anti-androgeen. - Google Patents

Dihydrospirorenon als anti-androgeen.

Info

Publication number
NL300221I2
NL300221I2 NL300221C NL300221C NL300221I2 NL 300221 I2 NL300221 I2 NL 300221I2 NL 300221 C NL300221 C NL 300221C NL 300221 C NL300221 C NL 300221C NL 300221 I2 NL300221 I2 NL 300221I2
Authority
NL
Netherlands
Prior art keywords
androgen
dihydrospirorenone
treatment
premenopause
oestrogen
Prior art date
Application number
NL300221C
Other languages
English (en)
Dutch (nl)
Other versions
NL300221I1 (nl
Original Assignee
Schering Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=6380839&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NL300221(I2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Schering Ag filed Critical Schering Ag
Publication of NL300221I1 publication Critical patent/NL300221I1/nl
Publication of NL300221I2 publication Critical patent/NL300221I2/nl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A61K31/585—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin containing lactone rings, e.g. oxandrolone, bufalin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Dental Preparations (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
NL300221C 1989-05-16 2006-02-03 Dihydrospirorenon als anti-androgeen. NL300221I2 (nl)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE3916112A DE3916112A1 (de) 1989-05-16 1989-05-16 Dihydrospirorenon als antiandrogen

Publications (2)

Publication Number Publication Date
NL300221I1 NL300221I1 (nl) 2006-04-03
NL300221I2 true NL300221I2 (nl) 2006-11-01

Family

ID=6380839

Family Applications (1)

Application Number Title Priority Date Filing Date
NL300221C NL300221I2 (nl) 1989-05-16 2006-02-03 Dihydrospirorenon als anti-androgeen.

Country Status (20)

Country Link
US (1) US5569652A (enExample)
EP (1) EP0398460B1 (enExample)
JP (1) JP2848919B2 (enExample)
CN (1) CN1033948C (enExample)
AT (1) ATE154881T1 (enExample)
AU (1) AU642876B2 (enExample)
BR (1) BR1101055A (enExample)
CA (1) CA2016780C (enExample)
DD (1) DD294417A5 (enExample)
DE (3) DE3916112A1 (enExample)
DK (1) DK0398460T3 (enExample)
ES (1) ES2106728T3 (enExample)
GR (1) GR3024861T3 (enExample)
HU (1) HU213408B (enExample)
IE (1) IE81143B1 (enExample)
IL (1) IL94416A (enExample)
LU (1) LU91065I2 (enExample)
NL (1) NL300221I2 (enExample)
PT (1) PT94038B (enExample)
ZA (1) ZA903754B (enExample)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4321957C2 (de) * 1993-07-01 1995-09-28 Marika Dr Med Ehrlich Verwendung eines hormonalen Mittels zur Therapie der Akne
DE4344462C2 (de) 1993-12-22 1996-02-01 Schering Ag Zusammensetzung für die Empfängnisverhütung
DE19651000A1 (de) * 1996-12-01 1998-06-04 Schering Ag Oxyiminopregnancarbolactone
US6787531B1 (en) * 1999-08-31 2004-09-07 Schering Ag Pharmaceutical composition for use as a contraceptive
EP1598069B1 (en) * 1999-08-31 2009-04-22 Bayer Schering Pharma Aktiengesellschaft Pharmaceutical combination of ethinylestradiol and drospirenone for use as a contraceptive
EP2305267A3 (en) 1999-08-31 2011-08-17 Bayer Schering Pharma Aktiengesellschaft Pharmaceutical combination of ethinylestradiol and drospirenone for use as a contraceptive
US20020132801A1 (en) * 2001-01-11 2002-09-19 Schering Aktiengesellschaft Drospirenone for hormone replacement therapy
EP1216713A1 (en) 2000-12-20 2002-06-26 Schering Aktiengesellschaft Compositions of estrogen-cyclodextrin complexes
EP1216712A1 (en) 2000-12-20 2002-06-26 Schering Aktiengesellschaft Cyclodextrin-drospirenone inclusion complexes
JP5350572B2 (ja) * 2000-12-20 2013-11-27 バイエル ファーマ アクチエンゲゼルシャフト シクロデキストリン−ドロスピレノン封入複合体
KR20040091141A (ko) * 2002-03-18 2004-10-27 파마시아 코포레이션 알도스테론 수용체 길항물질 및 니코틴산 또는 니코틴산유도체의 혼합물
WO2003080069A1 (en) * 2002-03-18 2003-10-02 Pharmacia Corporation Combination of an aldosterone receptor antagonist and a bile acid sequestering agent
WO2004070048A1 (en) * 2003-02-07 2004-08-19 Pharmacia & Upjohn Company Llc A microbial process to prepare 5-androsten-3beta, 7alpha, 15alpha-triol-17-one and related analogues
US20050220825A1 (en) * 2004-03-10 2005-10-06 Adrian Funke Molecular dispersions of drospirenone
CA2558393A1 (en) 2004-03-10 2005-09-22 Schering Aktiengesellschaft Compositions comprising drospirenone molecularly dispersed
MY142989A (en) * 2004-03-10 2011-02-14 Bayer Schering Pharma Ag Stabilised supersaturated solids of lipophilic drugs
DE102004026669A1 (de) * 2004-05-28 2005-12-15 Grünenthal GmbH Verwendung einer Kombination aus Ethinylestradiol und Chlormadinonacetat zur Herstellung eines Arzneimittels
DE102004026671A1 (de) 2004-05-28 2005-12-15 Grünenthal GmbH Darreichungsform zur hormonalen Kontrazeption
DE102004026670A1 (de) 2004-05-28 2005-12-15 Grünenthal GmbH Hormonales Kontrazeptivum enthaltend eine Kombination aus Ethinylestradiol und Chlormadinonacetat
DE102004026679A1 (de) 2004-05-28 2005-12-15 Grünenthal GmbH Hormonales Kontrazeptivum enthaltend eine Kombination aus Ethinylestradiol und Chlormadinonacetat
ITMI20042338A1 (it) * 2004-12-06 2005-03-06 Ind Chimica Srl Processo per la preparazione di drospirenone
US8475838B2 (en) * 2005-06-03 2013-07-02 Sandoz Ag Rapidly-dissolving pharmaceutical composition for inhibiting ovulation
US7319154B2 (en) 2005-07-21 2008-01-15 Bayer Schering Pharma Ag Process for the production of 3-oxo-pregn-4-ene-21, 17-carbolactones by the metal free oxidation of 17-(3-hydroxypropyl)-3, 17-dihydroxyandrostanes
PT1746101E (pt) * 2005-07-21 2008-10-27 Bayer Schering Pharma Ag Processo para o fabrico de 3-oxo-pregn-4-eno-21,17-carbolactonas por meio de oxidação isenta de metais de 17-(3-hidroxipropil)-3,17-di-hidroxiandrostanos
US20070275941A1 (en) * 2006-05-17 2007-11-29 Vladimir Hanes Salt sensitivity and prevention of hypertension with drospirenone
CN102083418A (zh) * 2008-04-24 2011-06-01 伊万斯彻有限公司 口服避孕药剂及其制备方法
RS62297B1 (sr) 2011-11-23 2021-09-30 Therapeuticsmd Inc Prirodne kombinovane hormonske supstitucione formulacije i terapije
US9301920B2 (en) 2012-06-18 2016-04-05 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US10806697B2 (en) 2012-12-21 2020-10-20 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10806740B2 (en) 2012-06-18 2020-10-20 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US20130338122A1 (en) 2012-06-18 2013-12-19 Therapeuticsmd, Inc. Transdermal hormone replacement therapies
US20150196640A1 (en) 2012-06-18 2015-07-16 Therapeuticsmd, Inc. Progesterone formulations having a desirable pk profile
US11266661B2 (en) 2012-12-21 2022-03-08 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10568891B2 (en) 2012-12-21 2020-02-25 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US11246875B2 (en) 2012-12-21 2022-02-15 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10471072B2 (en) 2012-12-21 2019-11-12 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10537581B2 (en) 2012-12-21 2020-01-21 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US9180091B2 (en) 2012-12-21 2015-11-10 Therapeuticsmd, Inc. Soluble estradiol capsule for vaginal insertion
RU2016143081A (ru) 2014-05-22 2018-06-26 Терапьютиксмд, Инк. Натуральные комбинированные гормонозаместительные составы и терапии
US10328087B2 (en) 2015-07-23 2019-06-25 Therapeuticsmd, Inc. Formulations for solubilizing hormones
US10286077B2 (en) 2016-04-01 2019-05-14 Therapeuticsmd, Inc. Steroid hormone compositions in medium chain oils
US9931349B2 (en) 2016-04-01 2018-04-03 Therapeuticsmd, Inc. Steroid hormone pharmaceutical composition
US11633405B2 (en) 2020-02-07 2023-04-25 Therapeuticsmd, Inc. Steroid hormone pharmaceutical formulations

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2652761C2 (de) * 1976-11-16 1985-11-21 Schering AG, 1000 Berlin und 4709 Bergkamen 15,16-Methylen-Spirolactone, Verfahren zu deren Herstellung und diese enthaltende Arzneimittel
DE3022337A1 (de) * 1980-06-11 1982-01-07 Schering Ag Berlin Und Bergkamen, 1000 Berlin Praeparate zur kontrazeption und zur behandlung gynaekologischer stoerungen
US4347245A (en) * 1981-05-26 1982-08-31 German Shapiro Spironolactone-containing composition and use thereof
JPS59139400A (ja) * 1983-01-31 1984-08-10 Shionogi & Co Ltd 抗アルドステロン活性ステロイド誘導体
DE3402329A1 (de) * 1984-01-20 1985-08-01 Schering AG, 1000 Berlin und 4709 Bergkamen 6,6-ethylen-15,16-methylen-3-oxo-17(alpha)-pregn-4-en-21,17-carbolactone, verfahren zu deren herstellung und diese enthaltende pharmazeutische praeparate
US4855289A (en) * 1984-06-04 1989-08-08 Wester Per O Combination of two active substances
US4729999A (en) * 1984-10-12 1988-03-08 Bcm Technologies Antiestrogen therapy for symptoms of estrogen deficiency
DE3615376A1 (de) * 1986-05-07 1987-11-12 Schering Ag 2,2;6,6-diethylen-3-oxo-17(alpha)-pregn-4-en-21,17-carbolactone, verfahren zu deren herstellung und diese enthaltende pharmazeutische praeparate
IE61236B1 (en) * 1986-07-15 1994-10-19 American Home Prod Combination dosage form for pre-menopausal women

Also Published As

Publication number Publication date
BR1101055A (pt) 2000-08-08
DE3916112C2 (enExample) 1992-04-30
ZA903754B (en) 1991-02-27
HUT54500A (en) 1991-03-28
PT94038A (pt) 1991-01-08
ATE154881T1 (de) 1997-07-15
DE59010730D1 (de) 1997-08-07
LU91065I2 (fr) 2004-03-30
IL94416A (en) 1997-07-13
CA2016780C (en) 2000-07-11
EP0398460A2 (de) 1990-11-22
EP0398460B1 (de) 1997-07-02
AU642876B2 (en) 1993-11-04
CA2016780A1 (en) 1990-11-16
HU903045D0 (en) 1990-09-28
HU213408B (en) 1997-06-30
JPH0395121A (ja) 1991-04-19
ES2106728T3 (es) 1997-11-16
DE122004000006I1 (de) 2006-06-08
JP2848919B2 (ja) 1999-01-20
CN1047299A (zh) 1990-11-28
AU5509490A (en) 1990-11-22
NL300221I1 (nl) 2006-04-03
US5569652A (en) 1996-10-29
EP0398460A3 (de) 1991-09-25
IL94416A0 (en) 1991-03-10
DD294417A5 (de) 1991-10-02
PT94038B (pt) 1997-06-30
GR3024861T3 (en) 1998-01-30
DE3916112A1 (de) 1990-11-22
DK0398460T3 (da) 1998-02-16
IE901738L (en) 1990-11-16
CN1033948C (zh) 1997-02-05
IE81143B1 (en) 2000-04-19

Similar Documents

Publication Publication Date Title
NL300221I1 (nl) Dihydrospirorenon als anti-androgeen.
BR9402902A (pt) Hormônio paratiróideo e raloxifeno, compostos e formulação farmacêutica.
MY132626A (en) CARBAZOLYL-SUBSTITUTED ETHANOLAMINES AS SELECTIVE ß-3 AGONISTS
NO943521L (no) Anvendelse av et pyrrolidinacetamidderivat for fremstilling av et terapeutikum
IT1238825B (it) Dispositivo per la correzione chirurgica dell'ametropia.
DE69125855D1 (de) Therapeutisch wirksame, örtliche anwendung von st1435
PL285854A1 (en) Therapeutical device, especially for treatment of sexual disorders in men
ES2108870T3 (es) Aparato de rehabilitacion de las funciones labiolinguales basado en la busqueda de una satisfaccion.
SU1637773A1 (ru) Устройство дл разработки голеностопного сустава
NO952912L (no) En ny osteoblastisk proliferativ faktor
EP0408525A3 (en) Use in therapy of 10-amino-5,6-dihydro-11h-dibenzo(b,e)azepine-6,11-dione and derivatives as drugs for use in the treatment of urinary incontinence
FR2651998B1 (fr) Table de support de brancard notamment destinee a l'equipement d'ambulances.
ES2039255T3 (es) Utilizacion de n-((1-etil-2-pirrolidinil)metil)-2-metoxi-5-sulfamoil-benzamida en el tratamiento de la esterilidad.
IT1228977B (it) Apparecchio fisioterapico per la cura della sterilita' femminile accertata e per la dilatazione indolore del canale cervicale.
IT1243947B (it) 2-azido-ornitina, sua preparazione e suo impiego in terapia
RU96100080A (ru) Лечение состояний, связанных с нарушением уровня паратгормона
Bogdanovich Compression osteosynthesis
RU95107865A (ru) Шина для лечения переломов челюсти
IT1241589B (it) Mezzi per il trattamento terapeutico dell'apnea durante il sonno
RU96103990A (ru) Способ лечения пневмокониозов
NO974941L (no) Ny anvendelse av (S)-adenosyl-L-metionin(SAMe)